Tercica: Growing Small
This article was originally published in Start Up
Executive Summary
Armed with a powerful, in-licensed late-stage molecule from Genentech, two-and-a half-year-old Tercica is about a year away from entering the eminently reachable market for treating short-stature children, a potentially significant segment of a $750 million annual US market. But unlike many start-up in-licensers that seek niche indications for their lead programs, Tercica won't be able to fly under the radar of the competition.
You may also be interested in...
For the Moment, Pharmion Helps Burnish Biotech's Image
Biotech's unique volatility and the intuition that risk will be rewarded when science and business manage to click for the benefit of patients are also powerful incentives--including for drugs that fall under Pharma's radar. That dynamic seems to be playing out for the moment for Pharmion--the rare standout in the score of recent biopharm IPOs--as it prepares to roll out its recently approved drug, Vidaza.
Starting in the Marketplace
InterMune spun out of Connetics three years ago to develop many small infectious disease indications for interferon gamma (Actimmune), which Genentech had virtually abandoned. Soon after InterMune was established, it received a pleasant surprise when Actimmune showed activity in idiopathic pulmonary fibrosis. That unexpected blockbuster market opportunity accelerated its growth, enabling the company to go public and raise over $450 million with which to expand its resources and clinical programs. With Actimmune as a model, InterMune has been able to in-license three other marketed and late-stage products. Now it wants to add preclinical or IND compounds to its portfolio. However, taking on early-stage risk to be able to capture a greater share of the upside of a drug puts the company in the same arena as many other in-licensors, one where its clinical and medical marketing expertise are less critical skill sets. Phase III data on Actimmune in IPF are expected in November. An early commercial success in this disease could make InterMune a player in M&A.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.